Monday, April 29, 2024
Home Client Page 36

Client

    Random
    Citius Pharma

    Citius Pharma (CTXR) $1.20. Price Target Upped to $4.00 at HC Wainright.

    Biotech News Editor / Curator -
    STREET INSIDER H.C. Wainwright analyst Vernon Bernardino raised the price target on Citius Pharmaceuticals...

    VERU Inc. (VERU) $24. High Risk, Minimal Reward?

    Client Editor / Curator -
    Pre-FDA Approval Play. The Shares Are Now in the Hands of Fast Money Traders. You Can't Kiss all the...

    GeoVax to Present at World Vaccine Congress, Thursday April 4th.

    Client Editor / Curator -
    Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company’s next-generation non-MRNA Covid-19 vaccine...
    Hapbee

    2021 Breakthrough Wearable Tech: Overview on Hapbee (HAPB, HAPBF) and its Vision

    Telehealth Editor / Curator -
    LIVE CHART https://youtu.be/X_DRzL6MAOU
    biotech stock review, zestra

    Innovus Pharma (INNV) Partners With Lavasta’s 150 Member Sales Force for Female Sexual Arousal!

    Biotech News Editor / Curator -
    Dubai based Lavasta is a pharmaceutical marketing company that offers niched unique medications based on the latest scientific innovations that defy current...

    Provention Biosciences (PRVB) Enters the Danger Zone.

    Client Editor / Curator -
    Chart Looks Beautiful - But Nervous is why, we use soft and dry. LIVE QUOTE We'll...
    1...343536Page 36 of 36

    Latest article

    Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

    Client Editor / Curator -
    Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!

    Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

    Client Editor / Curator -
    CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...

    GeoVax (GOVX) Launches Vaccine Manufacturing System.

    2024 Watch List Editor / Curator -
    GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System Manufacturing Process for Phase 3 and Commercial Production...
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.